Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment

Abstract Splenectomy is considered as one of the first-line treatments for symptomatic patients with splenic marginal zone lymphoma (SMZL). Between 1997 and 2012, 100 hepatitis C virus-negative patients with SMZL were treated by splenectomy as first-line treatment. At 6 months, all patients but thre...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2014-08, Vol.55 (8), p.1854-1860
Main Authors: Lenglet, Julien, Traullé, Catherine, Mounier, Nicolas, Benet, Claire, Munoz-Bongrand, Nicolas, Amorin, Sandy, Noguera, Maria-Elena, Traverse-Glehen, Alexandra, Ffrench, Martine, Baseggio, Lucile, Felman, Pascale, Callet-Bauchu, Evelyne, Brice, Pauline, Berger, Françoise, Salles, Gilles, Brière, Josette, Coiffier, Bertrand, Thieblemont, Catherine
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Female
Follow-Up Studies
Humans
Immunophenotyping
Lymphoma, B-Cell, Marginal Zone - diagnosis
Lymphoma, B-Cell, Marginal Zone - mortality
Lymphoma, B-Cell, Marginal Zone - surgery
Lymphoma, B-Cell, Marginal Zone - therapy
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Prognosis
Risk Factors
Splenectomy
Splenic marginal zone lymphoma
Splenic Neoplasms - diagnosis
Splenic Neoplasms - mortality
Splenic Neoplasms - surgery
Splenic Neoplasms - therapy
treatment
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Splenectomy is considered as one of the first-line treatments for symptomatic patients with splenic marginal zone lymphoma (SMZL). Between 1997 and 2012, 100 hepatitis C virus-negative patients with SMZL were treated by splenectomy as first-line treatment. At 6 months, all patients but three recovered from all cytopenias. The median lymphocyte count at 6 months and 1 year was 11.51 × 109/L and 6.9 × 109/L, respectively. Median progression-free survival (PFS) was 8.25 years. The 5-year and 10-year overall survival (OS) rates were 84% and 67%, respectively. Histological transformation occurred in 11% of patients, and was the only parameter significantly associated with a shorter time to progression (p = 0.0001). Significant prognostic factors for OS were age (p = 0.0356) and histological transformation (p = 0.0312). In this large retrospective cohort, we confirmed that splenectomy as first-line treatment in patients with SMZL corrected cytopenias and lymphocytosis within the first year and was associated with a good PFS.
ISSN:1042-8194
1029-2403
DOI:10.3109/10428194.2013.861067